• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Current and future developments in the treatment of virus-induced hypercytokinemia

tetano

Editor, Senior Moderator
Future Med Chem. 2017 Jan 27. doi: 10.4155/fmc-2016-0181. [Epub ahead of print]
[h=1]Current and future developments in the treatment of virus-induced hypercytokinemia.[/h] Wong JP[SUP]1[/SUP], Viswanathan S[SUP]1[/SUP], Wang M[SUP]2[/SUP], Sun LQ[SUP]3[/SUP], Clark GC[SUP]4[/SUP], D'Elia RV[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Emerging pathogenic viruses such as Ebola and Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) can cause acute infections through the evasion of the host's antiviral immune responses and by inducing the upregulation of inflammatory cytokines. This immune dysregulation, termed a cytokine storm or hypercytokinemia, is potentially fatal and is a significant underlying factor in increased mortality of infected patients. The prevalence of global outbreaks in recent years has offered opportunities to study the progression of various viral infections and have provided an improved understanding of hypercytokinemia associated with these diseases. However, despite this increased knowledge and the study of the infections caused by a range of emerging viruses, the therapeutic options still remain limited. This review aims to explore alternative experimental strategies for treating hypercytokinemia induced by the Ebola, avian influenza and Dengue viruses; outlining their modes of action, summarizing their preclinical assessments and potential clinical applications.


[h=4]KEYWORDS:[/h] emerging viruses; hypercytokinemia; treatment

PMID: 28128003 DOI: 10.4155/fmc-2016-0181
[PubMed - as supplied by publisher]
 
Back
Top Bottom